Tatva Chintan Pharma Chems Gears Up for Q3 Reveal on 21st January; Check Key Expectations Here

Name: Stock Advisory service In India
Brand: univest
Rating: 4.4 (197000 reviews)

Posted by : sachet | Tue Jan 20 2026

Tatva Chintan Pharma Chems Gears Up for Q3 Reveal on 21st January; Check Key Expectations Here

Click and Sign Up to Get Live Updates on Q3 Results

Tatva Chintan Pharma Chems, one of the most significant Indian conglomerates, is set to announce its Q3 FY26 results on 21st January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Table of Contents

Tatva Chintan Pharma Chems Q3 Results 2026 Preview

Tatva Chintan Pharma Chem’s revenue is expected to be in the range of ₹123.52 crore, a 47.94% YoY increase.
Profit After Tax, or PAT, is projected to fall by 0.00% YoY.
Tatva Chintan Pharma Chems’ EBITDA is expected to rise to ₹13.16 crore.
Net profit is ₹9.92 crore, a fall of 0.00% YoY

Tatva Chintan Pharma Chems Share Performance

Over the past six months, Tatva Chintan Pharma Chems’ share price has fallen by 3.17% to ₹1,715.00.
Moreover, over the past year, the stock has decreased by 0.86%.
Despite this weak short-term performance, Tatva Chintan Pharma Chems’ stock has delivered a financially sound 66.10% return over the past 5 years.
As of 20th January 2026, the stock traded at ₹1,715 per share.

Key Factors to Watch for Tatva Chintan Pharma Chems

Demand & Segment Growth: Trends in key product segments like Structure Directing Agents (SDA), Phase Transfer Catalysts (PTC), Pharma & Agro intermediates, and emerging segments like semiconductor chemicals and electrolyte salts. SDA demand tied to automotive emissions standards (Euro 7) is a key upside driver.
Capacity Expansion & Commercialisation: Progress on new plant capacity coming online (e.g., Jolva facility) and commercialization of new products, which can drive future volume growth and improve margins.
Profitability & Margins: Changes in EBITDA and net margins driven by product mix, operating leverage, and raw material costs, as well as the overall cost and pricing environment in speciality chemicals.
Market & Export Conditions: Export demand, global regulatory norms, geopolitical trade conditions (tariffs, protectionism), and competition from Chinese producers, all of which influence revenue and market access.

Final Thoughts

Tatva Chintan Pharma Chems will announce its Q3 FY26 results on 21st January 2026. Analysts expect 47.94% YoY revenue growth, a 0.00% fall in PAT, and a 0.00% rise in EBITDA. Tatva Chintan Pharma Chem focuses on manufacturing and exporting specialty chemicals for industries like pharma, agro, automotive, and energy storage.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!